The materials for DUPIXENT contained in this virtual exhibition are approved for use only in the United States of America. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the full Prescribing Information and/or the Summary of Product Characteristics (SmPC).

SKIP

EXPLORE THE FIRST AND ONLY DUAL INHIBITOR OF IL‑4 AND IL‑13 SIGNALING1

The mechanism of dupilumab action in asthma has not been established.

PATIENT CONVERSATION GUIDE

Use this guide during discussions
with your appropriate patients

VIEW MOA

Explore the science behind the mechanism of action of DUPIXENT

HEAR FROM THE EXPERTS

Dr Tan: Discussing the MOA of DUPIXENT


Dr Tan: Discussing a Patient Case for DUPIXENT


Dr Tan: Discussing Patient Demographics


Dr Sher: Discussing the Significant
Efficacy of DUPIXENT


Dr Sher: Discussing the Impact of Dual Inhibition


Dr Sher: Discussing the Impact of Type 2 Inflammation

OCS-DEPENDENT PATIENT
PROFILE

View the data and an appropriate
patient type for DUPIXENT

DUPIXENT MyWay®

Enrollment Video: Information to help your appropriate patients with the enrollment process


Delivery Video: See how your appropriate patients can access DUPIXENT

UPPER AND LOWER AIRWAY
INFLAMMATION

Download this asset to see the
potential of DUPIXENT

NOW AVAILABLE: DUPIXENT
300 mg PRE-FILLED PEN

Pre-filled Pen Flashcard


Dosing Card

APPROVED FOR 3 INDICATIONS


EXPLORE ADDITIONAL
INDICATIONS
SWIPE TO EXPLORE

EOS, eosinophils; OCS, oral corticosteroid.

Reference:

  1. DUPIXENT Prescribing Information.